Investor Presentaiton

Generic FDF Rebound; Market dynamics stable 149 249 Revenue Growth 393 332 285 2Q FY23 3Q FY23 4Q FY23 1Q FY24 2Q FY24 [Cr] ROW Global Filings 47 Canada 13 8 21 Y-o-Y 123% Q-o-Q16% EU 14 + 18 US 28 * Includes 13 Tentative approvals in US 10 38 14 61 ■ Approved ■Pending Comments ■ Revenues during Q2 increased, led by sharp recovery in the ARV business partly supported from stable price trend on sequential basis. While Developed market revenue increased on higher volumes ■ H1 revenues increased +24% with overall market dynamics across portfolio remaining healthy Higher volumes of existing products in Europe and New approvals from North America to drive FY24 revenues ■ Won 20% of recent NACO ARV tender ■ Small molecules DP capacities at 10 billion unit annually underlying capacity utilization gradually moving up ■ H1 FY24 Developed Market filings: 5 product dossiers were filed and a total of 4 approvals received (including Tentative approvals) 20 20 Laurus Q2 & H1 FY 2024 Investor Presentation | October 20, 2023 LAURUS Labs Knowledge. Innovation. Excellence

View entire presentation